Organigram Reports Third Quarter Fiscal 2024 Results
August 13, 2024
- Net revenue of $41.1 million increased 25% over the prior year period
- Adjusted EBITDA¹ of $3.5 million versus $(2.9) million over the prior year period
- Established European foothold with a strategic investment in Sanity Group, a leading German cannabis company
- Completed landmark clinical study on FAST™ nanoemulsion technology showing faster onset, improved bioavailability of ingestible products
- Pro-forma cash position of $173 million²
TORONTO–(BUSINESS WIRE)– Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 (“Q3 Fiscal 2024”).
THIRD QUARTER HIGHLIGHTS
- Third quarter net revenue increased…
